{
  "scores": {
    "systems_strategic": 3,
    "technical_rigor": 3,
    "clarity": 4,
    "novelty": 3
  },
  "passed": false,
  "fail_reasons": [
    "systems_strategic score below threshold",
    "technical_rigor score below threshold",
    "systems_strategic_below_threshold",
    "technical_rigor_below_threshold"
  ],
  "rationale": "",
  "hard_gates": {
    "has_technical_anchor": true,
    "has_systems_implication": true,
    "has_evaluative_judgment": true,
    "hype_or_vague": false,
    "ungrounded_factual_claims": false,
    "too_academic_summary": false,
    "too_influencer_style": false
  },
  "classification": {
    "pillar": "research_translation",
    "hook_type": "framework",
    "themes": [
      "regulatory landscape",
      "wearable devices",
      "FDA guidance"
    ]
  },
  "revision_notes": {
    "top_3_fixes": [
      "Enhance the technical depth by providing specific mechanisms and constraints related to validation protocols.",
      "Increase the strategic analysis by discussing the broader implications of the FDA's changes on the industry and healthcare systems.",
      "Clarify the post-market monitoring processes and their impact on reliability and safety."
    ],
    "line_edits": [
      "Add specific examples of validation protocols and their technical details.",
      "Discuss the potential failure modes of wearable devices and how they can be mitigated.",
      "Expand on the societal and clinical impacts of wearables beyond just wellness products."
    ],
    "missing_elements": [
      "More detailed discussion on the technical aspects of validation and post-market monitoring.",
      "Strategic implications for the broader healthcare ecosystem and industry trends.",
      "Specific mechanisms and constraints related to the FDA's guidance."
    ]
  },
  "tracking": {
    "one_sentence_summary": "The FDA's 2026 update clarifies the regulatory landscape for wearable devices, emphasizing the need for robust validation and transparency.",
    "key_claims": [
      "The FDA's guidance distinguishes between medical information and physiological signals.",
      "Clinical decision support tools now have more flexibility but introduce new challenges.",
      "General wellness products require rigorous validation to ensure accuracy and reliability."
    ],
    "systems_implications": [
      "Impact on the regulatory environment for wearable devices.",
      "Changes in how clinical decision support tools are classified and used.",
      "Increased emphasis on post-market monitoring and validation."
    ],
    "technical_anchors": [
      "Validation protocols for wearable devices.",
      "Mechanisms for ensuring accuracy and reliability of health metrics.",
      "Technical details of post-market monitoring processes."
    ],
    "repeated_phrases_candidates": [
      "rigorous validation",
      "transparency",
      "post-market monitoring"
    ]
  },
  "reasoning_trace": [
    "The draft provides a clear overview of the FDA's 2026 update but lacks deep technical detail and strategic analysis.",
    "The technical rigor could be improved by including specific mechanisms and constraints related to validation protocols.",
    "The strategic implications could be enhanced by discussing broader industry and healthcare system impacts.",
    "Clarity is strong due to the structured presentation and use of concrete examples.",
    "Novelty is moderate as the topic is timely but not groundbreaking."
  ],
  "revision_count": 2
}